ACPU
AERI

Arrowgrass Capital Partners (US)’s Aerie Pharmaceuticals AERI Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-151,350
Closed -$2.91M – 167
2019
Q3 		$2.91M Buy
+151,350
New +$3.47M 0.22% 106

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s AERI Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) sold out of Aerie Pharmaceuticals (AERI) in Q4 2019, closing a stake of 151,350 shares — an estimated $2.91M sold.

Arrowgrass Capital Partners (US) first reported a position in AERI in Q3 2019 and held it in 1 quarter. The position peaked at $2.91M in Q3 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q4 2019.

  • Arrowgrass Capital Partners (US) reported no remaining Aerie Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 151,350 Aerie Pharmaceuticals shares in Q4 2019, an estimated $2.91M.
  • Arrowgrass Capital Partners (US) first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Aerie Pharmaceuticals position peaked at $2.91M in Q3 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.